{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:50:06Z","timestamp":1787629806137,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.intimp.2024.111903","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T06:54:02Z","timestamp":1712213642000},"page":"111903","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The effect of Bruton\u2019s tyrosine kinase (BTK) inhibitor in the eosinophilic asthma model of mouse"],"prefix":"10.1016","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2834-3337","authenticated-orcid":false,"given":"YeJi","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo-Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung","family":"Jun Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae-Sim","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo","family":"Seob Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.111903_b0005","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/978-1-0716-1237-8_21","article-title":"Regulatory and IgE(+) B cells in allergic asthma","volume":"2270","author":"Oliveria","year":"2021","journal-title":"Methods Mol Biol."},{"issue":"17","key":"10.1016\/j.intimp.2024.111903_b0010","doi-asserted-by":"crossref","DOI":"10.3390\/cells11172764","article-title":"Current understanding of asthma pathogenesis and Biomarkers","volume":"11","author":"Habib","year":"2022","journal-title":"Cells."},{"issue":"3","key":"10.1016\/j.intimp.2024.111903_b0015","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1155\/2006\/189127","article-title":"Predictors of loss of asthma control induced by corticosteroid withdrawal","volume":"13","author":"Belda","year":"2006","journal-title":"Can Respir J."},{"key":"10.1016\/j.intimp.2024.111903_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.983852","article-title":"Monoclonal antibodies in the management of asthma: dead ends, current status and future perspectives","volume":"13","author":"Kardas","year":"2022","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.111903_b0025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol Cancer."},{"issue":"4","key":"10.1016\/j.intimp.2024.111903_b0030","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/humu.9228","article-title":"Identification of the bruton tyrosine kinase (BTK) gene mutations in 20 australian families with X-linked agammaglobulinemia (XLA)","volume":"23","author":"Velickovic","year":"2004","journal-title":"Hum Mutat."},{"key":"10.1016\/j.intimp.2024.111903_b0035","series-title":"Agammaglobulinemia","first-page":"99","article-title":"Bruton\u2019s tyrosine kinase (BTK) beyond B lymphocytes: a protein kinase with relevance in innate immunity","author":"Lopez-Herrera","year":"2015"},{"issue":"9","key":"10.1016\/j.intimp.2024.111903_b0040","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1172\/JCI138448","article-title":"Bruton's tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis","volume":"130","author":"Dispenza","year":"2020","journal-title":"J Clin Invest."},{"issue":"1","key":"10.1016\/j.intimp.2024.111903_b0045","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13045-022-01353-w","article-title":"BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies","volume":"15","author":"Alu","year":"2022","journal-title":"J Hematol Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2024.111903_b0050","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med."},{"issue":"4","key":"10.1016\/j.intimp.2024.111903_b0055","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/imm.13416","article-title":"The role of Bruton's tyrosine kinase in the immune system and disease","volume":"164","author":"McDonald","year":"2021","journal-title":"Immunology."},{"issue":"4","key":"10.1016\/j.intimp.2024.111903_b0060","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1183\/09031936.05.00090304","article-title":"S-carboxymethylcysteine normalises airway responsiveness in sensitised and challenged mice","volume":"26","author":"Takeda","year":"2005","journal-title":"Eur Respir J."},{"issue":"1","key":"10.1016\/j.intimp.2024.111903_b0065","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2353\/ajpath.2006.050291","article-title":"Adrenomedullin is a cross-talk molecule that regulates tumor and mast cell function during human carcinogenesis","volume":"168","author":"Zudaire","year":"2006","journal-title":"Am J Pathol."},{"issue":"10","key":"10.1016\/j.intimp.2024.111903_b0070","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41423-019-0270-9","article-title":"T-cell expression of Bruton's tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia","volume":"17","author":"Xia","year":"2020","journal-title":"Cell Mol Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2024.111903_b0075","doi-asserted-by":"crossref","first-page":"7706","DOI":"10.4049\/jimmunol.181.11.7706","article-title":"The phosphoinositide 3-kinase-dependent activation of btk is required for optimal eicosanoid production and generation of reactive oxygen species in antigen-stimulated mast cells","volume":"181","author":"Kuehn","year":"2008","journal-title":"J Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.111903_b0080","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1189\/jlb.0513307","article-title":"Bruton's tyrosine kinase\u2013an integral protein of B cell development that also has an essential role in the innate immune system","volume":"95","author":"L\u00f3pez-Herrera","year":"2014","journal-title":"J Leukoc Biol."},{"key":"10.1016\/j.intimp.2024.111903_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104441","volume":"148","author":"Nadeem","year":"2019","journal-title":"Pharmacol Res."},{"issue":"9","key":"10.1016\/j.intimp.2024.111903_b0090","doi-asserted-by":"crossref","first-page":"e0137641","DOI":"10.1371\/journal.pone.0137641","article-title":"Inhibition of BTK and ITK with ibrutinib is effective in the prevention of chronic graft-versus-host disease in mice","volume":"10","author":"Schutt","year":"2015","journal-title":"PLoS One."},{"issue":"6","key":"10.1016\/j.intimp.2024.111903_b0095","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jaci.2022.08.027","article-title":"Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria","volume":"150","author":"Maurer","year":"2022","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.intimp.2024.111903_b0100","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0065-2776(08)01006-7","article-title":"Interleukin 5 in the link between the innate and acquired immune response","volume":"101","author":"Takatsu","year":"2009","journal-title":"Adv Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2024.111903_b0105","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1128\/MCB.24.6.2455-2466.2004","article-title":"Expression and function of tec, itk, and btk in lymphocytes: evidence for a unique role for tec","volume":"24","author":"Tomlinson","year":"2004","journal-title":"Mol Cell Biol."},{"issue":"11","key":"10.1016\/j.intimp.2024.111903_b0110","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1172\/JCI75328","article-title":"Ibrutinib treatment ameliorates murine chronic graft-versus-host disease","volume":"124","author":"Dubovsky","year":"2014","journal-title":"J Clin Invest."},{"key":"10.1016\/j.intimp.2024.111903_b0115","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ctrv.2017.06.001","article-title":"Bruton's tyrosine kinase (BTK) as a promising target in solid tumors","volume":"58","author":"Molina-Cerrillo","year":"2017","journal-title":"Cancer Treat Rev."},{"issue":"6","key":"10.1016\/j.intimp.2024.111903_b0120","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/1074-7613(95)90065-9","article-title":"Altered T cell receptor signaling and disrupted T cell development in mice lacking itk","volume":"3","author":"Liao","year":"1995","journal-title":"Immunity."},{"issue":"1","key":"10.1016\/j.intimp.2024.111903_b0125","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1600-065X.2008.00741.x","article-title":"Bruton's tyrosine kinase (btk): function, regulation, and transformation with special emphasis on the PH domain","volume":"228","author":"Mohamed","year":"2009","journal-title":"Immunol Rev."},{"issue":"1","key":"10.1016\/j.intimp.2024.111903_b0130","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4049\/jimmunol.182.1.329","article-title":"Btk regulates B cell receptor-mediated antigen processing and presentation by controlling actin cytoskeleton dynamics in B cells","volume":"182","author":"Sharma","year":"2009","journal-title":"J Immunol."},{"issue":"16","key":"10.1016\/j.intimp.2024.111903_b0135","doi-asserted-by":"crossref","first-page":"10983","DOI":"10.1074\/jbc.274.16.10983","article-title":"Phosphatidylinositol 3-kinase-dependent membrane association of the Bruton's tyrosine kinase pleckstrin homology domain visualized in single living cells","volume":"274","author":"V\u00e1rnai","year":"1999","journal-title":"J Biol Chem."},{"issue":"3","key":"10.1016\/j.intimp.2024.111903_b0140","first-page":"1997","article-title":"ERK\/MAPK signalling pathway and tumorigenesis","volume":"19","author":"Guo","year":"2020","journal-title":"Exp Ther Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924004211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924004211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T03:59:29Z","timestamp":1719979169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924004211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":28,"alternative-id":["S1567576924004211"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111903","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of Bruton\u2019s tyrosine kinase (BTK) inhibitor in the eosinophilic asthma model of mouse","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.111903","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111903"}}